Patent details

LUC00151 Product Name: Romosozumab et ses dérivés pharmaceutiquement acceptables (EVENITY)

Basic Information

Publication number:
LUC00151
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP067519033
Legal Status:
Inactive
Application number:
LUC00151
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/19/1411/001-004
Marketing Authorization Type:
Marketing Authorization Date:
11/12/2019
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
16/03/2020
First Marketing Authorization date:
11/12/2019
Grant date:
15/02/2021
Activation date:
Publication date:
16/03/2020
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
28/04/2031
SPC Extension Expiration:
28/04/2031
Rejection date:
Withdrawal date:

Owner

From:
16/03/2020
 
 

Name:
AMGEN INC.
Address:
One Amgen Center Drive, Thousand Oaks, CA 91320, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
16/03/2020
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2020/05
Publication date:
09/04/2020
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2021/04
Publication date:
08/03/2021
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
30/04/2026
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
16/03/2020 General Document 66
16/03/2020 Application Form 4
15/02/2021 Publication 1
15/02/2021 Outgoing Correspondence 1
16/03/2020 Outgoing Correspondence 1
16/03/2020 General Document 1
15/02/2021 Certificate 1
16/03/2020 Publication 1
16/03/2020 General Document 3